Patients of Infertility
Conditions
Interventions
At a facility approved by the Japan Society of Obstetrics and Gynecology, oocyte retrieval is performed on couples who wish to undergo PGT-A after obtaining their informed consent. Takara Bio Inc. per
Sponsors
Handa Mika
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Infertile couples undergoing embryo transfer for which IVF or ICSI can be performed as an insured procedure, who wish to undergo PGT-A, and who meet the following selection criteria (1) to (3) and do not meet the exclusion criteria. (1) Patients with a history of repeated IVF or ICSI/embryo transfer (ART) failures (repeated ART failures) Selection Criteria (1) Patients with a history of repeated IVF or ICSI/EMT failures. (2) Able to obtain written consent to participate in the clinical research with his/her partner. (3) If the research subject and his/her partner are both at least 18 years of age. 2) Persons with a history of repeated miscarriages (habitual miscarriage (including repeated miscarriages)) Selection Criteria (1) Subjects with a history of repeated miscarriages and stillbirths (2) Persons who are able to obtain written consent for participation in clinical research together with their partners. 3) Both the research subject and his/her partner are at least 18 years of age. 3) Chromosomal structural abnormalities (e.g., balanced chromosome translocations) in either the research subject or his/her partner are confirmed (chromosomal structural abnormalities). Selection criteria (1) Chromosome structural abnormalities (t(11;22)(q23;q11) for balanced reciprocal translocations, rob(13;14) for Robertsonian translocations, etc.) are confirmed in the research subject or his/her partner. (2) Persons who are able to obtain written consent to participate in clinical research together with their partners. 3) Both the research subject and his/her partner are over 18 years old.
Exclusion criteria
Exclusion criteria: 1) Inappropriate ART patients with severe complications such as severe heart failure or other complications that are considered to have a significant potential to cause significant damage to maternal health during pregnancy and delivery 2) Patients who have undergone PGT-A/SR at least once in this study 3) Persons who have underwent embryotransfer in which has been performed PGT-A/SR in this study at least once 4) Other persons deemed inappropriate by the principal investigator or a physician who is a research participant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ongoing pregnancy rate at 12 gestational weeks to 13 gestational weeks in the study population underwent embryo transfer. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Early miscarriage rate at examination from 12 gestational weeks to 13 gestational weeks in the embryo transfer group 2) Implantation rate (including biochemical pregnancies) in the embryo transfer group 3) Clinical pregnancy rate per implantation (including biochemical abortions) in the embryo transfer group 4) Pregnancy loss rate per implantation (including biochemical abortions) in the embryo transfer group | — |
Contacts
Public ContactMika Handa
Osaka university
Outcome results
None listed